Health Economics›Neuroblastoma›High-risk upfront therapy

High-risk upfront therapy

Neuroblastoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG ANBL17P1 protocol Partial	—	R 193 688	50d	—	—	~5	~R 959 768 indirect	—
COG A3973 with Myeloablative Therapy Partial	—	R 151 461	28d	—	—	~6	~R 504 305 indirect	—
COG A3973 without Myeloablative Therapy	—	R 148 333	28d	—	—	~2	~R 250 249 indirect	—
COG ANBL0532 Regimen B Partial	—	R 102 298	28d	—	—	~7	~R 777 040 indirect	—
COG ANBL0532 Regimen A Partial	—	R 102 174	36d	—	—	~6	~R 201 901 indirect	—
COG ANBL0931 post-consolidation Variant not yet assigned - COG protocol Partial	—	R 14 144	28d	—	—	~2	~R 23 573 indirect	—
COG ANBL 0032 Regimen A Variant #01	—	R 2 669	25d	—	—	~6	~R 16 016 indirect	—

7 of 7 regimens shown